<DOC>
	<DOCNO>NCT03059147</DOCNO>
	<brief_summary>2.1 Primary Objectives 1 . To determine maximum tolerate dose ( MTD ) maximum recommend dose SF1126 adult patient advance ( unresectable metastatic ) HCC Child-Pugh A Child-Pugh B7 cirrhosis . 2 . To determine recommended phase II dose SF1126 patient advance ( unresectable metastatic ) HCC Child-Pugh A Child-Pugh B7 cirrhosis . 2.2 Secondary Objectives 1 . To describe safety tolerability SF1126 adult patient underlie liver disease ongoing evaluation adverse event . 2 . To determine pharmacokinetics HCC patient . 3 . To assess effect SF1126 progression-free survival overall survival . 2.3 Endpoints Primary Endpoint The primary endpoint rate dose limit toxicity ( DLTs ) within 56 day start treatment , maximum tolerate dose maximum recommend dose SF1126 .</brief_summary>
	<brief_title>A Study Single Agent SF1126 Inhibitor Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>SF1126 dual inhibitor phosphatidylinositol-3-kinase ( pan-isoform specific ) bromodomain-containing protein 4 ( BRD4 ) simultaneously disrupt two key MYC-mediating factor promote cancer cell growth .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>To qualify enrollment , follow criterion must meet : 1 . Willing able provide write informed consent prior performance studyspecific procedure . 2 . Age ≥ 18 year . 3 . Histological radiologic diagnosis advance ( unresectable metastatic ) HCC ChildPugh A ChildPugh B7 cirrhosis : 1 . The diagnosis HCC make accord European Association Study LiverEuropean Organization Research Treatment Cancer Clinical Practice Guidelines ( EASL EASLEORTC CPG ) accord successive modification American Association Study Liver Disease ( AASLD ) practice guideline . 2 . Pathological diagnosis HCC make accord International Working Party criterion . 4 . Is candidate local therapy , include liver transplantation , tumor ablation , transarterial embolization , resection . 5 . No known FDAapproved therapy available expect prolong survival great 3 month . 6 . ECOG Performance Status ≤ 2 . 7 . Has measurable evaluable disease per RECIST v1.1 . 8 . Life expectancy ≥ 12 week . 9 . Has recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy : Myelosuppressive chemotherapy : At least 3 week since completion ( 6 week nitrosourea ) Biologic ( antineoplastic agent ) : At least 7 day since completion therapy biologic agent . Radiation ( XRT ) : ≥ 1 week must elapse prior palliative XRT nontarget lesion . 10 . Inability tolerate firstline treatment sorafenib ( e.g. , unacceptable toxicity ) , tumor progression sorafenib , patient preference stop sorafenib alternative therapy/trial , patient preference forgo sorafenib alternative therapy/trial . 11 . Adequate Bone Marrow Function Defined subject ( include status post SCT ) : Peripheral absolute neutrophil count ( ANC ) ≥ 1000/mm3 Platelet count ≥ 50,000/mm3 Hemoglobin ≥ 8.0 g/dL ( may receive transfusion ) 12 . Adequate Renal Function Defined As : Serum creatinine ≤ 1.5 x institution 's ULN ( upper limit normal ) , Creatinine clearance ≥ 50 ml/min 13 . Adequate Liver Pancreatic Function Defined As : Total bilirubin ≤ 2.0 x upper limit normal , ALT AST ≤ 5 x upper limit normal , Albumin ≥ 2 g/dL 14 . Adequate Central Nervous System Function Defined As : Subjects seizure disorder may enrol anticonvulsant seizures well control . 15 . Female subject eligible enter study either : 1 . Of nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include woman : Has hysterectomy , Has bilateral oophorectomy , Has bilateral tubal ligation , Is postmenopausal ( demonstrate total cessation menses great equal 1 year ) . OR 2 . Of childbearing potential , negative serum pregnancy test screening , agree one follow contraceptive : An intrauterine device ( IUD ) document failure rate le 1 % per year . Vasectomized partner sterile prior subject 's entry sole sexual partner woman . Complete abstinence sexual intercourse 14 day exposure investigational product , clinical trial , least 14 day last dose investigational product . Double barrier contraception define condom spermicidal jelly , foam , suppository , film ; OR diaphragm spermicide ; OR male condom diaphragm . 16 . Male patient partner childbearing potential must agree use adequate contraception study 1 . Brain metastasis spinal cord compression , unless treatment complete least 4 week study entry , stable without steroid treatment least 4 week . 2 . Evidence severe uncontrolled systemic disease [ e.g. , unstable uncompensated respiratory , cardiac ( include life threaten arrhythmia ) ] . 3 . Unresolved toxicity ≥ CTCAE Grade 2 previous anticancer therapy except alopecia ( applicable ) unless agree patient enter discussion Medical Monitor . 4 . Presence cardiac impairment define : QTc prolongation define QTc ≥ 480 m ECGs ; OR prior history cardiovascular disease include heart failure meet New York Hearth Association ( NYHA ) class III IV definition ; OR history myocardial infarction/active ischemic heart disease within one year study entry ; OR uncontrolled dysrhythmias ; OR poorly control angina . 5 . Participation trial investigational agent within prior 30 day . 6 . Pregnant breastfeeding female . 7 . High volume peritoneal pleural effusion require tap frequently every 14 day . Moderate severe ascites . 8 . Poorly control refractory ( grade 34 ) hepatic encephalopathy . 9 . History malignancy except curatively excise carcinoma situ cervix , nonmelanoma skin cancer superficial bladder cancer solid tumor curatively treat evidence disease ≥ 5 year . Other case review possibly allow discuss approve Medical Monitor . 10 . Patients receive therapeutic dos warfarin . Lovenox permit . 11 . Criteria hypertension : Blood pressure great 170/90 2 SD normal base age weight nomogram 3 separate measurement . Uncontrolled HTN . 12 . Any concurrent condition investigator 's opinion make undesirable subject participate trial would jeopardize compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>